Letter of Intent
The first step in the application process is to submit a Letter of Intent providing the title of the proposed research or educational project, a 500-word description, and a budget estimate. Blank Letters of Intent can be downloaded from this web site all year round. Completed Letters of Intent should be submitted to the Program Administrator at programadministrator@bayer-hemophilia-awards.com. Timelines can be found under the section 'About the Program'.
Letters of Intent will be reviewed by all members of the Grants Review and Awards Committee. Applicants submitting acceptable Letters of Intent will be asked by the Committee to submit a full proposal.
Applicants invited to submit a full proposal will receive the full application form by e-mail.
DOWNLOAD A LETTER OF INTENT
Full Proposal
If your Letter of Intent is accepted by the Committee, you will receive, by e-mail, the full proposal form. The latter will be a Word document. You should complete the full proposal form before e-mailing the document to the Program Administrator. There may be a requirement for you to include other documents with your form, e.g. a CV. These should be cut and pasted into your form so that you submit a single Word document.
If a given section does not apply to your proposal, please write 'not applicable' in the appropriate space, so we can be sure it was not left blank in error.
Feedback from the Grants Review and Awards Committee is available to all individuals who complete a full proposal whether or not an award is made.
View the Browser Requirements for this site.
Click here to contact the Program Administrator if you have questions regarding this program or anything contained on this website.
We appreciate your interest in The Bayer Hemophilia Awards Program and in improving the lives of people with bleeding disorders. The Bayer Hemophilia Awards Program demonstrates Bayer's commitment to the bleeding disorders community and to advancing the state of the art of hemophilia care.
The Program is an important and reliable source of educational and research funding for health professionals in the bleeding disorders community.
We look forward to a continuing partnership with hemophilia caregivers and researchers around the world to support the next steps for the next generation of care and treatment options for people with hemophilia.
|
